Please ensure Javascript is enabled for purposes of website accessibility

"Better Than Nothing" Doesn't Cut It for Zalicus

By Brian Orelli, PhD – Updated Apr 7, 2017 at 1:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Zalicus' Synavive beats placebo, but not an active comparator.

First, the good news: In a phase 2b trial, Zalicus' (Nasdaq: ZLCS) Synavive passed its primary endpoint, improving patients' rheumatoid arthritis symptoms compared with placebo.

Despite the seemingly good news, Zalicus has decided to stop development of the drug.

For indications with high unmet need, beating placebo is usually good enough. But for diseases such as rheumatoid arthritis, being better than placebo just doesn't cut it. There are too many other options for patients.

In addition to being compared to placebo, Synavive was compared to its individual components -- prednisolone and dipyridamole -- as well as prednisolone, another drug commonly prescribed for rheumatoid arthritis. Unfortunately, the combination product didn't perform any better than prednisolone alone.

The company didn't release any information about whether Synavive beat the other active comparators, but it really doesn't matter. Even if the Food and Drug Administration would approve Synavive with just placebo data, no doctor would prescribe it if it isn't any better than prednisolone, which is available as a generic. Shelving the drug is really Zalicus' best move.

This bad news could be good for Pfizer (NYSE: PFE), Incyte (Nasdaq: INCY), and Rigel, which are all developing oral rheumatoid arthritis drugs that might have competed with Synavive. Pfizer is waiting to hear from the FDA on or before Nov. 21 about its drug tofacitinib. Incyte, with partner Eli Lilly (NYSE: LLY), and Rigel (partnered with AstraZeneca (NYSE: AZN)) aren't much further behind.

Losing its lead pipeline drug is a big hit for Zalicus; shares are down about 40% on the news. The company will need to hunker down and focus of its other pain medications: Z160, which just entered a phase 2 trial, and Z944 that's a little further behind. Without any major catalysts for about a year, investors buying the drop today have to be willing to hold for awhile.

The biggest binary event, the presidential election, is around the corner. Check out the Fool's new free report, "These Stocks Could Skyrocket After the 2012 Presidential Election," where you'll get ideas for companies that can benefit from each candidate's platform. Get your free copy by clicking here.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

EPIRUS Biopharmaceuticals, Inc. Stock Quote
EPIRUS Biopharmaceuticals, Inc.
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$323.35 (-2.02%) $-6.66
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$54.84 (-0.13%) $0.07
Pfizer Inc. Stock Quote
Pfizer Inc.
$43.76 (-0.91%) $0.40
Incyte Corporation Stock Quote
Incyte Corporation
$66.64 (0.04%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.